Volume | 4,167 |
|
|||||
News | - | ||||||
Day High | 2.49 | Low High |
|||||
Day Low | 2.43 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Minerva Neurosciences Inc | NERV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.45 | 2.43 | 2.49 | 2.4365 | 2.43 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
83 | 4,167 | $ 2.45 | $ 10,216 | - | 2.2864 - 13.49 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:39:14 | 10 | $ 2.42 | USD |
Minerva Neurosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
17.06M | 6.99M | - | 0 | -30.01M | -4.29 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Minerva Neurosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NERV Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.50 | 2.59 | 2.43 | 2.50 | 7,142 | -0.0635 | -2.54% |
1 Month | 2.58 | 2.80 | 2.2864 | 2.51 | 17,246 | -0.1435 | -5.56% |
3 Months | 8.55 | 13.49 | 2.2864 | 4.50 | 127,152 | -6.11 | -71.50% |
6 Months | 4.50 | 13.49 | 2.2864 | 4.87 | 73,071 | -2.06 | -45.86% |
1 Year | 2.31 | 13.49 | 2.2864 | 8.87 | 311,610 | 0.1265 | 5.48% |
3 Years | 2.42 | 15.27 | 0.327884 | 6.77 | 878,000 | 0.0165 | 0.68% |
5 Years | 7.29 | 15.27 | 0.327884 | 5.88 | 887,497 | -4.85 | -66.58% |
Minerva Neurosciences Description
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on the development of product candidates to treat patients suffering from central nervous system diseases. Minerva is developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop MIN-301 for the treatment of Parkinson's disease. Minerva co-developed seltorexant with Janssen Pharmaceutica NV for the treatment of insomnia disorder and adjunctive treatment of Major Depressive Disorder.Minerva has not received any regulatory approvals to commercialize its product candidates and has not generated any revenue from the sales or license of any product candidates. Minerva has incurred significant operating losses since inception and expects to continue to incur net losses and negative cash flows from operating activities for the foreseeable future in connection with clinical and regulatory activities. |